Anti-hyperlipidemic

Neoandrographolide
Catalog No: CFN97766

Neoandrographolide has antiradical, anti-inflammatory,and hypolipidemic effects, it protects the cardiovascular without significant liver damage. Neoandrographolide as chemosensitizer in S-Jurkat and X chromosome-linked inhibitor of apoptosis protein (XIAP)-overexpressing Jurkat cells, a model for chemoresistance.Neoandrographolide inhibits iNOS and COX-2 expression through inhibiting p38 MAPKs activation.
Obtusifolin
Catalog No: CFN90394

Obtusifolin is a novel anti-breast-cancer bone metastasis agent, which has antioxidant, and antinociceptive properties.Obtusifolin has beneficial effects on the development of diabetic retinopathy via inhibition of accumulation of oxidatively modified DNA and nitrotyrosine in the retina, can help prevent vision loss in diabetic patients. Gluco-Obtusifolin and its aglycone may be useful for the treatment of cognitive impairment, and that its beneficial effects are mediated, in part, by the enhancement of cholinergic signaling.
Pterostilbene
Catalog No: CFN90397

Pterostilbene acts as a peroxisome proliferator-activated receptor alpha (PPARalpha) agonist, it has been implicated in anticarcinogenesis, antioxidant, modulation of neurological disease, anti-inflammation, attenuation of vascular disease, and amelioration of diabetes. Pterostilbene downregulates inflammatory iNOS and COX-2 gene expression in macrophages by inhibiting the activation of NFkappaB by interfering with the activation of PI3K/Akt/IKK and MAPK. Pterostilbene may protect HUVECs against oxLDL-induced apoptosis by downregulating LOX-1-mediated activation through a pathway involving oxidative stress, p53, mitochondria, cytochrome c and caspase protease.
Mevastatin
Catalog No: CFN90426

Mevastatin inhibits HMGCR (HMG-CoA reductase) which in turn inhibits isoprenoid biosynthesis and therefore blocks protein isoprenylation and reduces plasma cholesterol levels in humans. Mevastatin inhibits the differentiation of TAO derived orbital preadipocytes by blocking PPAR-gamma mRNA expression. Mevastatin induces cell growth inhibition and apoptosis in SACC cells, it triggers the phosphorylation of the EGFR and inhibits the c-Jun N-terminal kinase pathway.
Simvastatin
Catalog No: CFN90427

Simvastatin is an FDA-approved cholesterol-lowering medication, it possesses potent anti-inflammatory property and has potent benefits on endothelial and smooth muscle cell-mediated vasomotor responses. Simvastatin rescues Aβ-mediated cerebrovascular and cognitive deficits. Simvastatin reduces burn-induced splenic apoptosis via downregulation of the TNF-α/NF-κB pathway, it induces p65 instability leads to MMP-9 down-regulation in leukemia cells, while it induces JNK1/c-Jun/ATF-2 activation maintains the MMP-2 expression underlying p65 down-regulation.